Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 31st 2012

Innovative Payment Models in Oncology Care

This article is based on the presentation by Peter B. Bach, MD, MAPP

December 31st 2012

Data Tracking and Point of Service Decision Support

This article is based on the presentation by Andrew L. Pecora, MD, FACP, CPE

December 31st 2012

Healthcare, the National Debt, and Taxes

This article is based on the presentation by Michael E. Chernew, PhD

December 9th 2012

Richard T. Hoppe, MD, Discusses the Current Role and Utility of Radiation Therapy

Richard T. Hoppe, MD, Professor of Radiation Oncology - Radiation Therapy, Stanford School of Medicine, discussed the current role and utility of radiation therapy in patients with early stage Hodgkins Lymphoma when compared to conventional chemotherapy.

December 6th 2012

Bigger Role Seen for Breast Cancer Drug

November 30th 2012

Appendix A -- Value of Survival Gains in Chronic Myeloid Leukemia

November 30th 2012

Dynamic Cost-Effectiveness of Oncology Drugs

Yang Lu, PhD John R. Penrod, PhD Neeraj Sood, PhD Saarah Woodby, BA Tomas Philipson, PhD

November 30th 2012

Value of Survival Gains in Chronic Myeloid Leukemia

Wesley Yin, PhD John R. Penrod, PhD J. Ross Maclean, MD Darius N. Lakdawalla, PhD Tomas Philipson, PhD

Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.

November 21st 2012

Payer Management of Oncology: An In-Depth Look

On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.

November 20th 2012

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

Katrina A.B. Goddard, PhD Erin J. Aiello Bowles, MPH Heather Spencer Feigelson, PhD, MPH Laurel A. Habel, PhD Sharon Hensley Alford, PhD Catherine A. McCarty, PhD, MPH Larissa Nekhlyudov, MD, MPH Adedayo A. Onitilo, MD, MSCR, FACP Alanna K. Rahm, PhD, MS Jennifer A. Webster, MS

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

November 20th 2012

Trends in the 2012 Eisai Oncology Digest: Insurance and Cost Obstacles in Cancer Treatment

This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned funded by Eisai Inc.

November 19th 2012

Payer Management of Oncology: An In-Depth Look

November 19th 2012

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

November 19th 2012

Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care

Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality.

November 19th 2012

Automated Telephone Calls to Enhance Colorectal Cancer Screening: Economic Analysis

David H. Smith, RPh, PhD Adrianne C. Feldstein, MD, MS Nancy Perrin, PhD A. Gabriela Rosales, MS David M. Mosen, PhD, MPH Elizabeth G. Liles, MD Jennifer L. Schneider, MPH Jennifer E. Lafata, PhD Ronald E. Myers, PhD Russell E. Glasgow, PhD

Automated telephone calls can increase colorectal cancer screening rates at a cost of about $40 per additional screen.

November 19th 2012

Mark Fendrick, MD, Discusses Value-Based Insurance Design

Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care.

November 16th 2012

Michael Chernew, PhD, Discusses Challenges in Oncology Management

Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.

November 16th 2012

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

November 16th 2012

Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships

Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management.

November 13th 2012

Celgene Stock Soars on Promising Pancreatic Cancer Drug Data

November 12th 2012

Not Enough Cancer Drugs, Too Many Price Controls

October 29th 2012

Pricey New Prostate Cancer Therapy Raises Questions About Safety, Cost

October 24th 2012

Change to FIT Increased CRC Screening Rates: Evaluation of a US Screening Outreach Program

Elizabeth G. Liles, MD, MSCR Nancy Perrin, PhD Ana Gabriela Rosales, MS Adrianne C. Feldstein, MD, MS David H. Smith, RPh, MHA, PhD David M. Mosen, PhD, MPH Jennifer L. Schneider, MPH

Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.

October 11th 2012

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

October 11th 2012

Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer

October 10th 2012

3-D Mammograms Offer a New Option for Breast Cancer Screening

October 5th 2012

The Evolving Role of the Pharmacist in Oncology Care

The role of the pharmacist in the care of patients with cancer is evolving. Pharmacists can help optimize treatment outcomes for each patient through use of patient-specific and disease-specific strategies.

October 3rd 2012

Cancer Treatment Speeded by Genome Superhighway: Creator

October 3rd 2012

Prostate-Cancer Test May Reduce Repeat Biopsies: Study

October 1st 2012

Roche's Breast Cancer Franchise Boosted by Trial Data

...

175 176 177 178 179 180 181 182 183

...

185 >